Growth Metrics

Novartis Ag (NVS) Free Cash Flow (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -43.19%
Dec 31, 2025 72.03%
Sep 30, 2025 -94.94%
Jun 30, 2025 2,653.94%
Mar 31, 2025 -96.70%
Dec 31, 2024 2,298.13%
Sep 30, 2024 -93.75%
Jun 30, 2024 2,162.11%
Mar 31, 2024 -96.73%
Dec 31, 2023 2,558.62%
Sep 30, 2023 -93.13%
Jun 30, 2023 2,162.50%
Mar 31, 2023 -97.06%
Dec 31, 2022 2,483.71%
Sep 30, 2022 -94.49%
Jun 30, 2022 1,461.09%
Mar 31, 2022 -96.18%
Dec 31, 2021 1,815.10%
Sep 30, 2021 -92.12%
Jun 30, 2021 1,710.16%
Mar 31, 2021 -96.49%
Dec 31, 2020 2,412.54%
Sep 30, 2020 -93.36%
Jun 30, 2020 1,671.73%
Mar 31, 2020 -48.59%
Dec 31, 2019 29.13%
Sep 30, 2019 -89.47%
Jun 30, 2019 1,102.13%
Mar 31, 2019 -36.49%
Dec 31, 2018 50.51%
Sep 30, 2018 -92.97%
Jun 30, 2018 1,527.52%
Mar 31, 2018 -59.56%
Dec 31, 2017 67.02%
Sep 30, 2017 -90.24%
Jun 30, 2017 1,037.79%
Mar 31, 2017 -41.30%
Dec 31, 2016 32.28%
Sep 30, 2016 -1.12%
Jun 30, 2016 16.36%
Mar 31, 2016 -48.87%
Dec 31, 2015 30.05%
Sep 30, 2015 102,296,719.79%
Jun 30, 2015 20.68%
Mar 31, 2015 -43.49%
Dec 31, 2014 24.25%
Sep 30, 2014 3.73%
Jun 30, 2014 33.61%
Sep 30, 2013 19.91%
Jun 30, 2013 27.36%
Sep 30, 2012 9.60%
Jun 30, 2012 46.60%
Mar 31, 2012 -47.52%
Dec 31, 2011 53.92%
Sep 30, 2011 12.58%
Jun 30, 2011 8.11%
Mar 31, 2011 -37.74%
Dec 31, 2010 94.51%
Sep 30, 2010 -2.54%
Jun 30, 2010 -90.17%
Mar 31, 2010 -100.00%
Dec 31, 2009 341,580,191.93%
Sep 30, 2009 15.02%
Jun 30, 2009 33.69%